Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 5, 2015, Pages 495-501

  Kim, Do Young ^a   Park, Beom Jin ^b   Kim, Yun Hwan ^b   Han, Kwang Hyub ^a   Cho, Sung Bum ^b   Cho, Kyu Ran ^b   Uhm, Sun Ho ^b   Choe, Jae Gol ^b   Choi, Jong Young ^c   Chun, Ho Jong ^c   Lee, Han Chu ^d   Gwon, Dong Il ^d   Lee, Kwang Hun ^a   Yoon, Jung Hwan ^e   Chung, Jin Wook ^e   Kim, Chang Won ^f   Heo, Jeong ^f   Kim, Jae Kyu ^g   Joo, Young Eun ^g  

^a Yonsei University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

^f Pusan National University School of Medicine   (South Korea)

^g Chonnam National University Medical School   (South Korea)

Author keywords

Hepatocellular carcinoma; Radioembolization; Yttrium 90

Indexed keywords

BILIRUBIN; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; BONE MARROW DEPRESSION; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EVALUATION STUDY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE PAIN; INSOMNIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN SEVERITY; PNEUMONIA; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; RISK ASSESSMENT; SURVIVAL PREDICTION; THORAX PAIN; TRANSARTERIAL CHEMOEMBOLIZATION; URTICARIA; VOMITING; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; SOUTH KOREA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84941881298     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182a78dba     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
3. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
4. Kim DY, Ryu HJ, Choi JY, et al. Radiologic response predicts survival following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012; 35: 1343-1350.
5. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
7. Kennedy A, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004; 60: 1552-1563.
8. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011; 79: 163-171.
9. Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastasis secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66(suppl): S62-S73.
10. Geschwind JF, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004; 127: S194-S205.
11. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90y microspheres (therasphere): Safety, tumor response, and survival. J Vasc Interv Radiol. 2005; 16: 1627-1639.
12. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90yresin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 792-800.
13. Kim DY, Kwon DS, Salem R, et al. Successful embolization of hepatocelluar carcinoma with yttrium-90 glass microspheres prior to liver transplantation. J Gastrointest Surg. 2006; 10: 413-416.
14. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140: 497-507, e492.
15. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011; 54: 868-878.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
17. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttriummicrospheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995; 33: 919-924.
18. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007; 68: 13-23.
19. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer. 1994; 70: 994-999.
20. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997; 24: 293-298.
21. Kennedy A, Coldwell D, Sangro B, et al. Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol. 2012; 35: 91-99.
22. Sangro B, Salem R, Kennedy A, et al. Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations. Am J Clin Oncol. 2011; 34: 422-431.
23. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol, Biol, Phys. 1998; 40: 583-592.
24. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: A phase II study. Hepatology. 2013; 57: 1826-1837.
25. Salem R, Lewandowski RJ, Mucahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology. 2010; 138: 52-64.
26. Memon K, Kulik L, Lewandowski RJ, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013; 58: 73-80.
27. Kim SH, Choi SB, Lee JG, et al. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011; 15: 598-607.